Torrent Pharmaceuticals received approval from India’s antitrust regulator, the Competition Commission of India (CCI). The approval allows it to acquire a majority stake in KKR-backed JB Chemicals. The CCI clearance comes with conditions. The regulator requires the parties to comply with voluntary modifications, which it will detail in its final order.
The company stated, “This is to inform you that the Competition Commission of India (CCI) has granted its approval for the transaction on 21st October 2025. The approval is subject to the parties complying with voluntary modifications, which will be outlined in CCI’s final order.”
Two-Phase Acquisition Plan
Torrent Pharma will execute the acquisition in two phases:
*Mandatory Open Offer: Torrent Pharma will first launch an open offer to acquire up to 26% of JB Chemicals’ shares from public shareholders.
*Employee Stake Acquisition: In the second phase, Torrent will acquire an additional 2.80% stake from company employees at the same price per share as KKR’s divestment.
Planned Merger with JB Chemicals
Following the share acquisition, Torrent Pharma intends to merge with JB Chemicals. Under the proposed arrangement. Every JB Chemicals shareholder holding 100 shares will receive 51 shares of Torrent Pharma. This move creates a seamless integration between the two companies.
Strategic Rationale
Samir Mehta, Executive Chairman of Torrent Pharma, highlighted, “Torrent’s deep India presence and JB Pharma’s fast-growing India business offer immense potential. Combined with the CDMO and international footprint, this provides opportunities to scale both revenue and profitability.” As reported by msn.com, the merger is expected to strengthen Torrent Pharma’s domestic operations. It will also expand its CDMO and international market capabilities.
